Biotechnology company Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) on Wednesday announced the publication of its second European patent application (Application No. 23821586.7, Publication No. EP4630038) titled "SIRT6 Variant for NASH" in the European Patent Bulletin. The filing follows entry into the European phase under the Patent Cooperation Treaty and represents a key milestone in the company's growing intellectual property portfolio.

Publication of the application grants provisional protection under Article 67(3) of the European Patent Convention, allowing Genflow to claim retroactive damages in designated EPC states for infringements occurring after publication, once the patent is granted and national validation completed.

The new patent strengthens Genflow's protection for its SIRT6 gene variant technologies and expands their potential therapeutic use in metabolic and age-related diseases, including non-alcoholic steatohepatitis (NASH). It complements the previously published European patent EP4338267, which covers Genflow's core SIRT6 variant for healthy ageing, establishing a strong European IP foundation for the company's platform and clinical pipeline.

Founded in 2020 and headquartered in the UK with R&D operations in Belgium, Genflow Biosciences is developing gene therapies aimed at slowing the ageing process. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene and is currently being evaluated in a 12-month proof-of-concept clinical trial in aged dogs. A further clinical programme is planned to assess GF-1002 in metabolic dysfunction-associated steatohepatitis (MASH), a major unmet medical need.